Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Leuven (Belgium), Strasbourg (France), Philadelphia (USA) -- April 14, 2023 /PRNewswire/- Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Flamingo will present preclinical results highlighting the candidate selection and characterization of FTX-001, a novel antisense oligonucleotide targeting MALAT1 for the treatment of cancer.  Flamingo is currently advancing FTX-001 through Phase 1 enabling preclinical activities and is planning for a First-in-Human trial in solid tumors.

Details of the poster presentation are below:

Title:Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1”

Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM - 5:00 PM
Location: Poster Section 16
Poster Board Number: 14
Published Abstract Number: 450

Abstracts and full session details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR

About Flamingo Therapeutics

Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants.  Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.

Flamingo is initiating a Phase II trial ‘PEMDA-HN’ evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC).

For more information on Flamingo, please visit and engage with us on LinkedIn

Flamingo Media and Investor Contact:

Amy Conrad
Juniper Point
(858) 366-3243